Evidence map›Paper›PMID 36994196›Full record

ArticleFrontiers in oncology2023

Case Report: A case of

Linghui Lu, Shunni Wang, Haoran Shen, Feiran Zhang, Fenghua Ma, Yue Shi, Yan Ning

Open access · goldFull text readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in oncology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
3.1field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 12 citations in OpenAlex.

  1. Gynecologic oncology reports · 2023
    Article
  2. Uterine tumor resembling high-grade endometrial mesenchymal sarcoma with GATAD2B-MMRN1 fusion.International journal of clinical and experimental pathology · 2023
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Linghui LuDepartment of Pathology, Obstetrics and Gynecology Hospital of Fudan University, Shanghai, China.
Shunni WangDepartment of Pathology, Obstetrics and Gynecology Hospital of Fudan University, Shanghai, China.
Haoran ShenDepartment of Gynecological Oncology, Obstetrics and Gynecology Hospital of Fudan University, Shanghai, China.
Feiran ZhangDepartment of Pathology, Obstetrics and Gynecology Hospital of Fudan University, Shanghai, China.
Fenghua MaDepartment of Radiology, Obstetrics and Gynecology Hospital of Fudan University, Shanghai, China.
Yue ShiDepartment of Gynecological Oncology, Obstetrics and Gynecology Hospital of Fudan University, Shanghai, China.
Yan NingDepartment of Pathology, Obstetrics and Gynecology Hospital of Fudan University, Shanghai, China.
Obstetrics and Gynecology Hospital of Fudan University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

COL1A1-PDGFB fusiondermatofibrosarcoma protuberans (DFSP)NTRK fusionRNA sequencingtarget therapyuterine sarcoma

Identifiers

PMID36994196
PMCPMC10042132
OpenAlexW4324046020

What OpenQuestion holds

Textfull text, public
LicenceCC BY
measurements read17
identifiers read2
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.